UY27003A1 - Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer - Google Patents
Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimerInfo
- Publication number
- UY27003A1 UY27003A1 UY27003A UY27003A UY27003A1 UY 27003 A1 UY27003 A1 UY 27003A1 UY 27003 A UY27003 A UY 27003A UY 27003 A UY27003 A UY 27003A UY 27003 A1 UY27003 A1 UY 27003A1
- Authority
- UY
- Uruguay
- Prior art keywords
- alzheimer
- disease
- diagnosis
- radiopharmaceutical products
- radiopharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
Uso de productos radiofarmacéuticos en el diagnóstico de la enfermedad de Alzheimer. En particular, los productos radiofarmacéuticos de la invención tienen la capacidad para atravesar la barrera hematoencefálica y unirse al receptor CCR1 presente en el tejido del cerebro de pacientes que padecen la enfermedad de Alzheimer
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24629900P | 2000-11-06 | 2000-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY27003A1 true UY27003A1 (es) | 2002-07-31 |
Family
ID=22930075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY27003A UY27003A1 (es) | 2000-11-06 | 2001-10-31 | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
Country Status (29)
Country | Link |
---|---|
US (2) | US6676926B2 (es) |
EP (1) | EP1332138B1 (es) |
JP (1) | JP4234425B2 (es) |
KR (1) | KR20030045167A (es) |
CN (1) | CN1473158A (es) |
AR (1) | AR035366A1 (es) |
AT (1) | ATE314354T1 (es) |
AU (2) | AU2002214034B2 (es) |
BG (1) | BG107762A (es) |
BR (1) | BR0115150A (es) |
CA (1) | CA2424598A1 (es) |
DE (1) | DE60116365T2 (es) |
EA (1) | EA006199B1 (es) |
EE (1) | EE200300216A (es) |
HR (1) | HRP20030459A2 (es) |
HU (1) | HUP0301710A3 (es) |
IL (1) | IL155191A0 (es) |
JO (1) | JO2207B1 (es) |
MX (1) | MXPA03003759A (es) |
NO (1) | NO20032007L (es) |
NZ (1) | NZ525303A (es) |
PE (1) | PE20020531A1 (es) |
PL (1) | PL361631A1 (es) |
SK (1) | SK287495B6 (es) |
TW (1) | TWI238820B (es) |
UY (1) | UY27003A1 (es) |
WO (1) | WO2002036581A1 (es) |
YU (1) | YU33203A (es) |
ZA (1) | ZA200304409B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY27003A1 (es) * | 2000-11-06 | 2002-07-31 | Schering Ag | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
PL370548A1 (en) | 2001-10-22 | 2005-05-30 | Pfizer Products Inc. | Piperazine derivatives with ccr1 receptor antagonist activity |
EP1465869B1 (en) | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulators of lxr |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
DE502004006670D1 (de) * | 2003-05-07 | 2008-05-08 | Bayer Schering Pharma Ag | Vorrichtung und verfahren zum nucleophilen fluorieren |
US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
AU2005216949B2 (en) * | 2004-02-24 | 2011-09-22 | The General Hospital Corporation | Catalytic radiofluorination |
US8257680B1 (en) | 2004-02-24 | 2012-09-04 | The General Hospital Corporation | Catalytic radiofluorination |
GB0409236D0 (en) * | 2004-04-26 | 2004-05-26 | Novartis Ag | Organic compounds |
US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
KR100778888B1 (ko) * | 2005-11-29 | 2007-11-28 | 재단법인서울대학교산학협력재단 | 베타아밀로이드 펩타이드 플라크의 영상화를 위한벤질리덴아닐린 계열의 유도체 및 그의 방사성 동위원소표지화합물 |
AU2007292883B2 (en) | 2006-09-08 | 2013-09-05 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced brain disease |
AU2007292874B2 (en) | 2006-09-08 | 2013-11-21 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced liver disease |
GB0625523D0 (en) | 2006-12-21 | 2007-01-31 | Ge Healthcare Ltd | In vivo imaging agents |
JP5562036B2 (ja) * | 2006-12-21 | 2014-07-30 | ハマースミス・イメイネット・リミテッド | 放射性標識方法 |
EP2211911A4 (en) * | 2007-10-31 | 2012-11-14 | Alseres Pharmaceuticals Inc | METHOD FOR DIAGNOSIS AND MONITORING OF THE TREATMENT OF LEWY BODILY DAMAGE BY EVALUATING THE DOPAMIN TRANSPORTER MIRROR |
CN102046638B (zh) | 2008-03-21 | 2015-06-03 | 综合医院公司 | 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物 |
EP2161256A1 (en) * | 2008-09-08 | 2010-03-10 | Atomic Energy Council - Institute of Nuclear Energy Research | Compound containing carboxylate ester and N2S2 ligand bi-functional groups and manufacturing method thereof |
EP2163541A1 (en) * | 2008-09-12 | 2010-03-17 | Bayer Schering Pharma Aktiengesellschaft | Piperazine derivatives for binding and imaging amyloid plaques and their use |
WO2011041470A2 (en) * | 2009-09-30 | 2011-04-07 | Mallinckrodt Inc. | Sustained-release opiate and opiate derivative compositions |
TW201201846A (en) * | 2010-02-08 | 2012-01-16 | Bayer Schering Pharma Ag | Iodo precursor for a PET imaging agent of amyloid plaques |
WO2011110511A1 (en) * | 2010-03-11 | 2011-09-15 | Bayer Pharma Aktiengesellschaft | Spect imaging agents of amyloid plaques |
US9572787B2 (en) | 2011-05-19 | 2017-02-21 | Rhode Island Hospital | Inhibition of renal fibrosis |
JP6584322B2 (ja) | 2013-12-27 | 2019-10-02 | 国立大学法人 東京医科歯科大学 | アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法 |
US10137211B2 (en) * | 2015-08-28 | 2018-11-27 | Chdi Foundation, Inc. | Probes for imaging Huntingtin protein |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU654013B2 (en) * | 1991-03-13 | 1994-10-20 | Regents Of The University Of Minnesota | 2-hydroxy-3(4-iodophenyl)-1-(4-phenylpiperidinyl) propane |
EP0524146A1 (de) | 1991-07-19 | 1993-01-20 | Ciba-Geigy Ag | Aminosubstituierte Piperazinderivate |
GB9413772D0 (en) | 1994-07-08 | 1994-08-24 | Wyeth John & Brother Ltd | 5-HT1A ligands |
US5919797A (en) * | 1996-04-24 | 1999-07-06 | Emory University | Halogenated naphthyl methoxy piperidines for mapping serotonin transporter sites |
WO1998002151A2 (en) | 1996-07-12 | 1998-01-22 | Leukosite, Inc. | Chemokine receptor antagonists and methods of use therefor |
FR2758328B1 (fr) | 1997-01-15 | 1999-04-02 | Pf Medicament | Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments |
US6207665B1 (en) * | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
AUPP278498A0 (en) * | 1998-04-03 | 1998-04-30 | Australian Nuclear Science & Technology Organisation | Peripheral benzodiazepine receptor binding agents |
US6288083B1 (en) | 1998-09-04 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
AUPP818099A0 (en) | 1999-01-14 | 1999-02-11 | Fujisawa Pharmaceutical Co., Ltd. | New n-containing heterocyclic compounds |
KR20010108394A (ko) | 1999-03-26 | 2001-12-07 | 다비드 에 질레스 | 신규 화합물 |
UY27003A1 (es) * | 2000-11-06 | 2002-07-31 | Schering Ag | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer |
-
2001
- 2001-10-31 UY UY27003A patent/UY27003A1/es not_active Application Discontinuation
- 2001-11-01 AU AU2002214034A patent/AU2002214034B2/en not_active Ceased
- 2001-11-01 EE EEP200300216A patent/EE200300216A/xx unknown
- 2001-11-01 AT AT01982450T patent/ATE314354T1/de not_active IP Right Cessation
- 2001-11-01 KR KR10-2003-7006187A patent/KR20030045167A/ko not_active Application Discontinuation
- 2001-11-01 CA CA002424598A patent/CA2424598A1/en not_active Abandoned
- 2001-11-01 NZ NZ525303A patent/NZ525303A/en unknown
- 2001-11-01 IL IL15519101A patent/IL155191A0/xx unknown
- 2001-11-01 WO PCT/EP2001/012607 patent/WO2002036581A1/en not_active Application Discontinuation
- 2001-11-01 BR BR0115150-9A patent/BR0115150A/pt not_active IP Right Cessation
- 2001-11-01 YU YU33203A patent/YU33203A/sh unknown
- 2001-11-01 PL PL01361631A patent/PL361631A1/xx not_active Application Discontinuation
- 2001-11-01 EA EA200300507A patent/EA006199B1/ru not_active IP Right Cessation
- 2001-11-01 HU HU0301710A patent/HUP0301710A3/hu unknown
- 2001-11-01 DE DE60116365T patent/DE60116365T2/de not_active Expired - Lifetime
- 2001-11-01 SK SK547-2003A patent/SK287495B6/sk not_active IP Right Cessation
- 2001-11-01 MX MXPA03003759A patent/MXPA03003759A/es unknown
- 2001-11-01 AU AU1403402A patent/AU1403402A/xx active Pending
- 2001-11-01 CN CNA01818409XA patent/CN1473158A/zh active Pending
- 2001-11-01 JP JP2002539340A patent/JP4234425B2/ja not_active Expired - Fee Related
- 2001-11-01 EP EP01982450A patent/EP1332138B1/en not_active Expired - Lifetime
- 2001-11-02 AR ARP010105127A patent/AR035366A1/es unknown
- 2001-11-05 JO JO2001178A patent/JO2207B1/en active
- 2001-11-05 PE PE2001001092A patent/PE20020531A1/es not_active Application Discontinuation
- 2001-11-06 TW TW090127552A patent/TWI238820B/zh not_active IP Right Cessation
- 2001-11-06 US US09/985,938 patent/US6676926B2/en not_active Expired - Fee Related
-
2003
- 2003-04-25 BG BG107762A patent/BG107762A/xx unknown
- 2003-05-05 NO NO20032007A patent/NO20032007L/no unknown
- 2003-06-05 ZA ZA200304409A patent/ZA200304409B/en unknown
- 2003-06-06 HR HR20030459A patent/HRP20030459A2/hr not_active Application Discontinuation
- 2003-07-25 US US10/626,725 patent/US6872381B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY27003A1 (es) | Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer | |
AR058327A1 (es) | Vacuna terapeutica | |
DE60126923D1 (de) | Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika | |
DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
BRPI0515175A (pt) | método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer | |
GT200500378A (es) | Macrolidos | |
CR9995A (es) | Anticuerpos monoclonales bifuncionales contra la placa beta amiloide | |
CL2007001918A1 (es) | Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras. | |
BRPI0507684A (pt) | agentes de contraste para formação de imagem de perfusão miocárdica | |
AR003989A1 (es) | Composicion cosmetica o farmaceutica y procedimiento de tratamiento cosmetico, excluido tdo tratamiento terapeutico que utiliza la composicion cosmetica. | |
TW200716208A (en) | Modified and immediate release memantine bead formulation | |
CY1111359T1 (el) | Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer | |
CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
EA200700427A1 (ru) | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний | |
BRPI0406883A (pt) | Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto | |
DE60143857D1 (de) | Zusammensetzung bestehend aus phy906 und chemotherapeutika | |
HK1087394A1 (en) | Methods of 11c radiolabelling phenothiazine and pheno thiazine-like compounds | |
WO2001092283A3 (en) | Cobalamin compounds useful as cardiovascular agents and as imaging agents | |
BRPI0414565A (pt) | composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato | |
CL2008001820A1 (es) | Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer. | |
HUP0401903A2 (hu) | Az ET-743 továbbfejlesztett alkalmazása daganatok kezelésére | |
HN2000000050A (es) | Sal mutua de amlodipino y atorvastatina | |
CL2004001068A1 (es) | Compuestos derivados de 2,3,4,5-tetrahidrobenzo[f][1,4]oxazepina; procedimientos de preparacion; composicion farmaceutica que los contiene y su uso en la elaboracion de un medicamento util para el tratamiento de la enfermedad de alzheimer. | |
CY1111361T1 (el) | Νεα προσδεματα συναγωνιστες των υποδοχεων rar, χρηση στην ανθρωπινη ιατρικη καθως και στην κοσμετολογια | |
PE20040176A1 (es) | Ambroxol para el tratamiento de dolores cronicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150414 |